IPAMORELIN 2000mcg

Ipamorelin 2000mcg is a synthetic hexapeptide that has been shown to have high growth hormone secreting potency and efficacy in animal studies.^1,2 Ghrelin and ipamorelin have comparable pharmacological effects in animals despite their distinct structures. Ipamorelin acts on the growth hormone secretagogue receptor (GHS-R) to trigger growth hormone release from the cells of the anterior pituitary gland. Through this mechanism, ipamorelin induces body weight gain in animals. In a lab study, injecting rats with comparable doses of growth hormone, growth hormone releasing peptides, and ipamorelin for 8 weeks resulted in significant (to the baseline value) and comparable growth.³Ipamorelin has also been linked to normal bone growth and structure. The effects of ipamorelin, growth hormone, and other growth hormone releasing peptides were tested on bone growth in rats for 8 weeks. Results showed that ipamorelin was associated with a significant increase in bone mineral content (tested by post-mortem bone scans). Although ipamorelin-induced bone growth was less than that induced by growth hormone, it was more than other growth hormone releasing peptides and the control group treatment.³ In addition to growth hormone, other comparable molecules raise levels of adrenocorticotropic hormone (ACTH) and cortisol in animal studies, but ipamorelin does not.¹ As a result, ipamorelin is more target specific than other comparable molecules, making it a better choice for in vitro research. Furthermore, ipamorelin does not influence luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, or thyroid-stimulating hormone (TSH) levels.¹ Ipamorelin, like ghrelin, has been found to improve diabetes in animal models by increasing insulin-like growth factor (IGF-I) release.⁴ In both diabetic and non-diabetic rats, the peptide was shown to boost insulin production in the pancreatic tissue.⁴ Ipamorelin comes as a lyophilized white powder in a vial with a total concentration of 2000 micrograms.

References: Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. 2. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999 Sep;16(9):1412-6. 3. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. 4. Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6.